Parenteral Manual

CARBOplatin

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
PARAPLATIN®, CBDCA, JM
Classification: 
Antineoplastic, alkylator - CYTOTOXIC
Original Date: 
June 2015
Revised Date: 
November 2023
Indications: 
  • Ovarian carcinoma
  • Under investigation for use in other malignancies (e.g., relapsed or high risk solid tumors in children)

THIS MEDICATION IS TO BE ADMINISTERED BY A CHEMO-TRAINED NURSE. IF THE NURSE IS NOT CHEMO-TRAINED, THEY ARE TO CONTACT THE UNIT NURSE EDUCATOR OR ADVANCED PRACTICE NURSE.

Reconstitution and Stability: 
  • 10 mg/mL solution, no reconstitution required
  • DO NOT expose to bright light for extended periods of time
  • Use only IV sets and needles which do not contain aluminum
  • Diluted solutions stable for 8 hours room temperature or 24 hours refrigerated
Compatibility: 

- Solutions Compatible: D5W, 0.9% NaCl

- Additives/Above Cassette Compatible: no information

- Y-site Compatible: ondansetron, filgrastim, potassium, TPN

- Incompatible: DO NOT MIX with any other drug

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM NO
IV Push

NO
IV Intermittant Infusion YES
Usual dilution: dilute in 50-100 mL
Infusion time: 30-60 minutes
IV Continuous Infusion NO
Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • 400-600 mg/m2 IV Q 3-4 weeks
  • Lower dosage when used to potentiate radiotherapy
  • Use mg/kg dosing for children <3 years of age or <12 kg
  • Dosing based on target AUC- use modified Calvert formula (refer to protocol for details)

** dosage may differ according to protocol

Dose adjustment in renal failure:

  • Dosage should be reduced in renal failure (use Calvert formula)
  • If GFR is <60 mL/minute/1.73 m2 consider discontinuing drug
Potential hazards of parenteral administration: 

Immediate (within a few minutes to hours):

  • Nausea and vomiting (moderate) - starting approximately 6 hours after treatment and lasting 12-24 hours
  • Allergic reaction: rare
  • Metallic taste
  • If extravasation occurs, see Treatment of Infiltrated Vesicant or Irritant Drugs Guidelines on CHEOnet.

Delayed (within a few weeks to months):

  • Myelosuppression, particularly thrombocytopenia - nadir 21 days (dose limiting toxicity)
  • nephrotoxicity - not usually dose limiting, transient increases in serum creatinine may occur; some patients have decreases in creatinine clearance
  • Hypomagnesemia, hypokalemia in some patients
  • Infrequent:  neurotoxicity, ototoxicity, alopecia, skin rash
  • Increase in liver function test
  • Non-vesicant

- Treatment for unusual side effects are available through the study chair identified on the front page of the protocol and/or pharmacy

Notes: 
  • Monitor renal function, hematologic status, serum electrolytes
  • Audiogram as per protocol for monitoring high frequency hearing loss
  • An analogue of cisplatin
  • Less nephrotoxic, ototoxic, neurotoxic than cisplatin
  • High volume hydration is not necessary to prevent nephrotoxicity (as with cisplatin), however, patients should be adequately hydrated
  • Myelosuppression may be enhanced in patients with preexisting renal impairment or myelosuppression - reduce dose or withhold treatment in these patients
  • Contraindicated in patients with history of severe allergic reaction to platinum containing compounds
  • Modified Calvert formula uses uncorrected GFR in mL/min, and the result is the total dose, not the dosage in mg/m2

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.